Use of estramustine phosphate co-administered with a taxane for treatment of cancer

摘要

Described is the use of estramustine phosphate and its metabolites estramustine and estromustine to potentiate the therapeutic efficacy of taxanes by both improving their pharmacokinetic and pharmacodynamic profile through the inhibition of (CYP)2C8 and (CYP)3A4 enzymes, both responsible for the metabolism of the taxanes. Also described are formulations of estramustine phosphate and metabolites, and combinations of the latter with taxanes for a treatment comprising them as a combined therapy.